MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ
0.4648
+0.0007
+0.15%
After Hours: 0.4610 -0.0038 -0.82% 19:40 05/29 EDT
OPEN
0.4632
PREV CLOSE
0.4641
HIGH
0.4980
LOW
0.4632
VOLUME
53.80K
TURNOVER
0
52 WEEK HIGH
1.869
52 WEEK LOW
0.4300
MARKET CAP
2.22M
P/E (TTM)
-0.1712
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SLRX last week (0520-0524)?
Weekly Report · 2d ago
Weekly Report: what happened at SLRX last week (0513-0517)?
Weekly Report · 05/20 11:13
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024
Salarius Pharmaceuticals reported earnings per share of -41 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -$ for the same period. Salarius pharmaceuticals is a subsidiary of AstraZeneca.
Investorplace · 05/14 02:53
SALARIUS PHARMACEUTICALS, INC. - QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Press release · 05/14 00:12
Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Salarius Pharmaceuticals Inc reported a quarterly adjusted loss of 41 cents per share for the quarter ended in March. The company's reported revenue was zero; analysts expected zero. The median 12-month price target for salarius pharmaceuticals Inc is $. Salarius PharmaceuticalS Inc shares have fallen by this quarter and so far this year.
Reuters · 05/13 22:02
Weekly Report: what happened at SLRX last week (0506-0510)?
Weekly Report · 05/13 11:24
Weekly Report: what happened at SLRX last week (0429-0503)?
Weekly Report · 05/06 11:31
Weekly Report: what happened at SLRX last week (0422-0426)?
Weekly Report · 04/29 11:38
More
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.

Webull offers Salarius Pharmaceuticals Inc stock information, including NASDAQ: SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.